ETON PHARMACEUTICALS INC (ETON)
US29772L1089 - Common Stock
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing...
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak...
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is...
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eton Pharmaceuticals (NASDAQ:ETON) just reported results for the fourth quarter...
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growthFull...
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company...
Eton announces commercial availability of Nitisinone capsules (NASDAQ:ETON)
Eton Pharmaceuticals (ETON) said Nitisinone capsules are now commercially available for the treatment of the ultra-rare disorder tyrosinemia type 1. Read more here.
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Current Nitisinone market is estimated to exceed...
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty...
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing,...
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to...
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing...